Table 1 Baseline characteristics.
Azilsartan (N = 94) | Candesartan (N = 95) | |
|---|---|---|
Male (%) | 50 (53.2) | 58 (61.1) |
Age (years) | 75.0 (70.0 − 80.0) | 76.0 (69.0 − 81.0) |
BMI (kg/m2) | 23.7 (21.5 − 26.1) | 24.3 (22.0 − 26.6) |
NYHA (I/II/III/IV), % | 6.4/92.6/1.1/0 | 11.6/86.3/2.1/0 |
Smoking (current/past), % | 3.2/43.6 | 9.5/45.3 |
Alcohol drinking (%) | 44 (46.8) | 55 (57.9) |
eGFR (mL/min/1.73 m2) | 57.1 (48.7 − 69.8) | 53.0 (42.2 − 63.1) |
E/e′ | 13.1 (10.5 − 15.7) | 13.3 (10.2 − 16.1) |
LVEF ≥ 50%, % | 95.3 | 94.3 |
Previous HF admission (%) | 23 (24.5) | 27 (28.4) |
Hypertension (%) | 85 (90.4) | 87 (91.6) |
Diabetes mellitus (%) | 40 (42.6) | 38 (40.0) |
Dyslipidemia (%) | 66 (70.2) | 63 (66.3) |
Any cause of cancer (%) | 15 (16.0) | 16 (16.8) |
COPD (%) | 2 (2.1) | 5 (5.3) |
Kidney disease (%) | 16 (17.0) | 20 (21.1) |
History of CVD (%) | 17 (18.1) | 30 (31.6) |
Principal cause of HF-no. (%) | ||
Hypertensive | 62 (66.0) | 72 (75.8) |
Ischemic | 19 (20.2) | 19 (20.0) |
Valvular | 8 (8.5) | 2 (2.1) |
Cardiomyopathy | 4 (4.3) | 1 (1.1) |
Others | 1 (1.1) | 1 (1.1) |
Device therapy-no. (%) | ||
Pacemaker | 6 (6.4) | 3 (3.2) |
Defibrillator | 1 (1.1) | 0 |
CRT | 0 | 0 |
Medications-no. (%) | ||
ACE inhibitor | 4 (4.3) | 2 (2.1) |
ARB | 53 (56.4) | 49 (51.6) |
Beta-blocker | 56 (59.6) | 60 (63.2) |
Diuretic | 32 (34.0) | 37 (38.9) |
MRA | 12 (12.8) | 13 (13.7) |
Ca blocker | 50 (53.2) | 54 (56.8) |
SGLT2 inhibitor | 6 (6.4) | 7 (7.4) |
